1,356 results on '"Fowler, Nathan"'
Search Results
2. Procrustes is a machine-learning approach that removes cross-platform batch effects from clinical RNA sequencing data
3. Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase 1/2 trial
4. Comprehensive peripheral blood immunoprofiling reveals five immunotypes with immunotherapy response characteristics in patients with cancer
5. Immune-depleted tumor microenvironment is associated with poor outcomes and BTK inhibitor resistance in mantle cell lymphoma
6. Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update
7. Multi-omic profiling of follicular lymphoma reveals changes in tissue architecture and enhanced stromal remodeling in high-risk patients
8. Efficacy and safety of tisagenlecleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: results from the phase 2 ELARA trial
9. B-Cell Infiltrate in the Tumor Microenvironment Is Associated With Improved Survival in Resected Lung Adenocarcinoma
10. Closing classification gaps in luminal breast cancer with single-cell RNA-seq insights from normal breast lineages.
11. Integrated genomic and transcriptomic characterization of neuroendocrine carcinomas for improved treatment decision-making.
12. An unsupervised H&E-based machine-learning approach for precise prediction of tumor microenvironment subtypes.
13. Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma
14. Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma
15. Targeting the Tumor Microenvironment
16. STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial
17. Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma
18. SIRPα+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab
19. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
20. Autologous stem cell transplantation for large B-cell lymphoma with secondary central nervous system involvement
21. Ibrutinib–rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial
22. Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma
23. Gastric Cancer Tumor Immune Microenvironment Landscape: Clinical Implications for Patient Outcome and Response to PD-1 Immune Checkpoint Blockade
24. Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 Elara 3-Year Follow-up
25. Long-Term Durable Responses in Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-Cell Lymphoma (DLBCL), and Follicular Lymphoma (FL) Treated with Tisagenlecleucel and Its Association with Persistence of Chimeric Antigen Receptor (CAR) T Cells
26. A Prospective Trial of Radiation Therapy Efficacy and Toxicity for Localized Mucosa-associated Lymphoid Tissue (MALT) Lymphoma
27. Kinase Inhibitors in Large Cell Lymphoma
28. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma
29. Integrative genomic analysis identifies unique immune environments associated with immunotherapy response in diffuse large B cell lymphoma
30. Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r/r follicular lymphoma
31. Role of the tumor microenvironment in mature B-cell lymphoid malignancies
32. Test-the-Test: Clinical Utility of Comprehensive Whole Exome Sequencing and RNA-Seq for Patients with Lymphoma
33. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study
34. 555 Challenges in predicting ICI response in HPV+ HNSCC: insights into the tumor microenvironment
35. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas
36. Primary central nervous system lymphoma in patients with and without HIV infection : a multicenter study and comparison with U.S national data
37. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma
38. Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia
39. Hematologic Malignancies Affecting the Temporal Bone
40. Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma
41. Outcomes After Reduced-Dose Intensity Modulated Radiation Therapy for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma
42. Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma
43. Early Stage Extranodal Follicular Lymphoma: Characteristics, Management, and Outcomes
44. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial
45. Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy
46. POSTER: CT-564 ELARA Trial Update: Long-Term Clinical Outcomes and Correlative Efficacy Analyses of Tisagenlecleucel in Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL)
47. CT-564 ELARA Trial Update: Long-Term Clinical Outcomes and Correlative Efficacy Analyses of Tisagenlecleucel in Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL)
48. CD8 T-cell dysfunction is linked with CAR T-cell failure and can be mitigated by a non-alpha IL-2 agonist, pegenzileukin
49. P1205: A LIVING PATIENT-DERIVED BIOREPOSITORY FOSTERING MICROENVIRONMENT DISSECTION IN T-CELL LYMPHOMA
50. Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.